Adam Lamble
Seattle Children's Hospital
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Adam Lamble as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 15:46 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT05476770 · Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic MalignanciesTherapeutic Advances in Childhood Leukemia Consortium · recruiting · Hematologic Malignancy, AML, ALL · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-11 15:46 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 15:46 UTC. The ranking covers the 200 most relevant of 5 PubMed records, and a shared surname and initials can bring in a namesake. All 5 on PubMed
- Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma.N Engl J Med · 2024230 citationsRCR 27.8
- 87 citationsRCR 4.9
- Drug-regulated CD33-targeted CAR T cells control AML using clinically optimized rapamycin dosing.J Clin Invest · 202452 citationsRCR 5.5
- Hematopoietic Stem Cell Transplantation Outcomes for High-Risk AML: A Report From the Children's Oncology Group.J Clin Oncol · 202511 citationsRCR 2.8
- Three-Year Follow-Up of Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Adolescents With Advanced-Stage Classic Hodgkin Lymphoma on S1826.J Clin Oncol · 20265 citationsRCR 2.5